Navigation Links
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Date:9/22/2009

BERLIN, Sept. 22 /PRNewswire/ -- Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC). These data were presented in an oral session at the joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology (ECCO 15 - 34th ESMO). Preliminary results from this study were presented earlier this year at the 45th American Society of Clinical Oncology (ASCO) Annual Congress, May 29 - June 2, 2009, Orlando, Florida.

"Bayer is committed to researching and developing potential anti-cancer agents like regorafenib, which may eventually help physicians and patients manage this devastating disease," said Kemal Malik, MD, Member of the Board of Management of Bayer Schering Pharma AG and Head of Global Development. "We look forward to continuing the comprehensive clinical development program for regorafenib, which we believe could potentially represent a promising new treatment option for various tumor types."

At the time of data analysis, 81 percent of patients (n=48) in the trial experienced disease stabilization or regression. Specifically, 31 percent of patients (n=15) experienced a confirmed partial response (PR), according to the Response Evaluation Criteria in Solid Tumors (RECIST), and 50 percent of patients (n=24) experienced stable disease (SD). The data also showed an estimated median progression-free survival of 8.3 months at the time of protocol-defined end of study. Importantly, the time of data analyses, which occurred on May 31, 2009, was prospectively defined in the protocol as when the last patient was treated for at least six months. At the time of analysi
'/>"/>

SOURCE Bayer HealthCare
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Ameritox SM , ... the appointment of Thomas Smith , M.D., as ... a field-based team offering scientific resources for healthcare providers, ... has held leadership positions at a variety of healthcare ... benefit both the pain and behavioral health sides of ...
(Date:10/17/2014)... Oct. 17, 2014   ndd Medical Technologies , ... employing precise ultrasound technology, announced that its EasyOne Pro® ... Healthcare Center , a 140,000 square foot, 44-bed hospital ... hospital serves a large number of Native ... Oklahoma and beyond. A portion of its ...
(Date:10/17/2014)... , Oct. 17, 2014  STAAR Surgical Company (NASDAQ: ... lenses and delivery systems for the eye, today announced that ... Meeting on Saturday, October 18, 7:00 a.m. CT at the ... Chicago, IL. Dr. Erik Mertens ... in Antwerp, Belgium , will present his ...
Breaking Medicine Technology:Ameritox Appoints New Chief Medical Officer 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting 2STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting 3
... 13, 2011 Pharma Major Lupin Limited announced today ... with the 2011 DIANA Award by the Healthcare Distribution ... Manufacturer among those companies with sales of up to ... The DIANA award winners are selected by HDMA ...
... 2011 Enox Biopharma, Inc., a leader in the ... devices, today announced that it has received notification from ... "Device and Method for Administering Therapeutic Agents" has been ... Enox acquired this patent from its Swedish Inventors, ...
Cached Medicine Technology:HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 2HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 3Enox Biopharma, Inc. Will Be Granted a Patent for the Delivery of Therapeutic Agents From Within Medical Devices 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 It’s hard to ... many orphans and vulnerable children around the world, it’s a ... some people, many children are forced to walk barefoot on ... their families or play with their friends. , Buckner ... with Air1 Radio in October to encourage support ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... , ST. LOUIS, Aug. 24 ... herbicide Atrazine have attorney and clean water advocate Steve Tillery ... and accountability for the herbicide,s manufacturers. , , ... the New York Times and the Peoria Journal Star have ...
... , , , OAKLAND, ... LATINA Style magazine on the publication,s list of the 50 ... , The LATINA Style survey, now in ... the value of diversity in the workplace, and identifies the corporations in ...
... Institute of Allergy and Infectious Diseases (NIAID), a component ... applications for a new initiative to establish a consortium ... these cooperative centerswhich together will receive funding up to ... immune system under normal conditions and to understand how ...
... - Concussions, whether from an accident, sporting event, or ... mental processes. Scientists have debated for centuries whether concussions ... changes that merely impair the way brain cells function, ... at Albert Einstein College of Medicine of Yeshiva University ...
... State University study shows that invigorated and dedicated employees ... home life. K-State psychology researchers studied how positive ... interactions. They found that employees who are engaged in ... dedication and absorption in daily activities, have better moods ...
... , SWARTZ CREEK, Mich., Aug. ... Health Services Division is partnering with CareSource in Ohio to ... outcomes and reduce healthcare costs associated with the disease. As ... is focused on the early identification and treatment of their ...
Cached Medicine News:Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 3Health News:Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 2Health News:Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 3Health News:NIAID to fund new human immune profiling research centers 2Health News:Strong link found between concussions and brain tissue injury 2Health News:Strong link found between concussions and brain tissue injury 3Health News:Researchers find that employees who are engaged in their work have happier home life 2Health News:Diplomat Specialty Pharmacy Partners With CareSource -- Launches Chronic Kidney Disease Management Program with Ohio Plan 2
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: